Interaction of Cyclometallated Ru(II) Drugs with Glutathione by Chen, Olivia
 INTERACTION OF CYCLOMETALLATED Ru(II) DRUGS WITH GLUTATHIONE 
 
HONORS RESEARCH THESIS  
 
Presented in partial fulfillment of the requirements for graduation with Honors Research 
Distinction in the College of Arts and Sciences at The Ohio State University 
 
By 
 
Olivia M. Chen 
Undergraduate Program in Molecular Genetics 
 
The Ohio State University 
May 2013 
 
 
Thesis Committee:  
Professor Claudia Turro, Advisor 
Professor Terry Gustafson 
Professor Anil Pradhan 
 
  
 
 
 
 
 
Copyright 
Olivia M. Chen 
2013 
 
 
 
 
 
 
 
   i 
ABSTRACT 
 
Photodynamic therapy (PDT) utilizing light to activate metal complexes has emerged 
as an alternative strategy of cancer treatment that imparts greater specificity of toxicity. In 
the realm of PDT, light-activated inorganic metal complexes that covalently bind DNA have 
come to the fore as potential anticancer therapies. The cyclometallated complex cis-
[Ru(phpy)(phen)(CH3CN)2]+ (1: phpy– = deprotonated 2-phenylpyridine, phen = 1,10-
phenanthroline) was recently found to inhibit tumor growth in mice with fewer major side 
effects. Treatment of the human ovarian cancer cell line OVCAR-5 with 1, resulted in a 
fourteen-fold increase in toxicity in irradiated conditions as compared to dark conditions. 
Despite this large photoinduced increase in toxicity of 1, the photophysical properties as well 
as the photoactivating mechanism are not fully understood; hence, both have been 
investigated for complex 1 and for the analog cis-[Ru(phpy)(bpy)(CH3CN)2]+ (2: bpy = 2,2´-
bipyridine). Within the cell, there is the possibility of ligand exchange occurring in the 
presence of coordinating solvent and a large intracellular pool of reduced glutathione (GSH), 
therefore the possible role that GSH may play in facilitating the production of toxic species 
was explored for 1 and 2. Both complexes 1 and 2 undergo ligand exchange in the presence 
of GSH in the dark. The observed cytotoxicity of 1 may be explained by both GSH-
facilitated ligand dissociation and photo-induced ligand exchange.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1  BACKGROUND 
The anti-cancer agent cisplatin, cis-Pt(NH3)2Cl2, is an inorganic metal complex that has 
been widely employed to treat a range of cancers, including ovarian and testicular malignancies. 
Cisplatin is thermally activated and covalently binds cellular DNA, inhibiting DNA replication 
among other cellular processes, which results in the death of tumor cells; however, the 
nonspecific thermal activation of cisplatin also leads to the death of healthy cells. Patients 
undergoing cisplatin treatment frequently experience side effects including altered hepatic 
functioning, neurotoxicity, nephrotoxicity, and weight loss.1 Multiple attempts to treat recurrent 
tumors with cisplatin or prolonged treatment with cisplatin, are often unsuccessful due to the 
increased resistance of cancer cells to the drug.17 These drawbacks of cisplatin have made other 
cancer treatments with greater specificity toward tumor cells a more attractive alternative. 
In photochemical reactions, the absorption of a photon supplies the energy that excites a 
molecule from the ground state to the excited state. Excited molecules can drive chemical 
reactions that may not be accessible otherwise, such as the ligand exchange observed in many 
Ru(II) and Rh2(II,II) compounds. When this occurs in the presence of coordinating solvent, 
photolabile ligands may be exchanged with surrounding solvent molecules. These photochemical 
reactions offer several practical advantages over thermally activated reactions, which occur at 
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ambient temperature. First, light energy can be used to overcome large energy of activation 
barriers to generate photoproducts. Second, utilizing light to initiate a chemical reaction enables 
restriction of the reaction and the generated products to a specific locale. This advantage of 
photoinduced reactions makes light-activated compounds particularly amenable to applications 
in many fields, including medicine.  
 The use of photoinitiated reactions in the medical field has emerged as a promising 
approach for treating microbial infections as well as malignant cancers.2,3 The potential that 
photoactivated compounds hold as therapeutics has spurred the growth of the PDT field, 
especially with regard to treating cancer. Light-activated compounds used in photochemotherapy 
exhibit a relatively low level of toxicity in the dark, but a high level of toxicity once irradiated. 
The use of light to selectively activate the compound allows for the toxic effects to be localized 
to the region requiring treatment, for instance, the tumor site. This enhanced specificity of 
activation reduces the adverse side effects posed by treatment. An additional advantage in 
photochemotherapy lies in the less invasive nature of such treatments; the drug is administered 
intravenously and an endoscope is used to deliver light to the tumor site. These advantageous 
qualities of PDT have encouraged continued exploration of light-activated compounds for PDT 
cancer therapies. 
 
1.2  PHOTODYNAMIC THERAPY AGENTS 
There are several important qualities that should be considered in order to identify 
suitable PDT agents.4 First, compounds should absorb light within the PDT window (600 – 850 
nm). Low energy light within this visible to near-infrared range is not greatly absorbed by water 
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or biomolecules such as hemoglobin within the body and therefore provides the deepest tissue 
penetration by light. Second, photoactivation of the PDT agent should have a high quantum 
yield, which is a measure of the efficiency of the PDT agent in using light energy to generate the 
photoproduct. Third, the PDT agent must be relatively nontoxic in the dark, but upon selective 
irradiation the photoproducts should be toxic. Organic compounds exhibiting these qualities were 
some of the first FDA-approved PDT agents for chemotherapy. 
Porfimer sodium, a hematoporphyrin derivative, has been used to treat a variety of 
cancers including esophageal, bladder, head, and neck cancers.5 The drug is injected 
intravenously in the dark and is relatively nontoxic in this condition. After uptake by cells, the 
treatment site is irradiated with low energy light. The excited porfimer sodium molecules within 
this region transfer energy to surrounding triplet oxygen, thereby producing singlet oxygen, a 
reactive oxygen species (ROS) that causes cell damage and eventual cell death. The mechanism 
of action of Porfimer sodium is illustrated in Figure 1.  
 
 
 
 
 
Figure 1. Low energy light excites porfimer sodium, which relaxes with 
concomitant production of a cell-damaging reactive oxygen species. 
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While organic PDT agents have proven useful in treating many different cancers, organic 
PDT compounds like Porfimer sodium require the presence of oxygen in the surrounding 
environment to generate tumor cell killing species, singlet oxygen, 1O2; the latter produces 
reactive oxygen species (ROS). As a result, the utility of these organic PDT agents is limited to 
treating cancers found in well-oxygenated environments.6,7 Unfortunately, many aggressive, 
malignant cancers exist in hypoxic surroundings.6,7 As a result, PDT agents that can operate 
through oxygen-independent mechanisms are being explored as potential treatments against 
these hypoxic cancers. Several light-activated inorganic compounds have been shown to possess 
oxygen-independent cell-killing mechanisms among other desirable qualities for PDT agents.8,9,10 
Some of these photoactive inorganic compounds function like organic compounds and kill cells 
through the production of ROS, while others are activated by light to covalently bind to DNA 
through singular or dual-binding mechanisms.9 DNA binding inhibits cellular processes 
including transcription and DNA replication, leading to eventual cell death. A better 
understanding of the photoactive mechanism and photophysical properties of these light-
activated inorganic complexes is therefore important for advancing the development of a line of 
treatments effective against resilient, hypoxic cancers.   
Of particular interest are light-activated inorganic compounds that readily bind DNA upon 
selective irradiation. This class of the light-activated inorganic compounds operates under a 
similar mechanism of action as the older chemotherapeutic drug cisplatin, cis-[Pt(NH3)2Cl2]. 
Cisplatin was first identified as possessing chemotherapeutic properties in the 1970s. In the cell, 
the complex undergoes thermal activation and exchanges its two Cl– ligands for water molecules. 
The intermediate complex cis-[Pt(NH3)2(H2O)Cl]+ is first formed, followed by formation of the 
activated bis-aqua complex cis-[Pt(NH3)2(H2O)2]2+. Water forms weak bonds with Pt(II) and is 
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easily displaced, allowing Pt(II) to covalently bind to adjacent purine residues of DNA, forming 
1,2-intrastrand adducts that cause the double helix to kink.11 DNA repair machinery fails to repair 
this kinked DNA and affected cells cannot proliferate and instead induce cell death.  The mode of 
action of cisplatin is illustrated in Figure 2. 
 
 
 
Figure 2. Thermal activation of Cisplatin leading to DNA binding.  
 
Though cisplatin is an oxygen-independent chemotherapeutic agent that has been widely 
used to kill tumors, the complex is thermally activated and therefore lacks specificity for tumor 
cells. This is a major disadvantage that leads to serious side effects and damage to healthy tissue 
and rapidly dividing cells in the body. Despite this drawback, the DNA-binding mechanism of 
cisplatin can be a useful mechanism to attain cell death if the chemistry is able to be controlled, 
such as through the use of light.  Therefore, compounds that can bind to DNA only when 
irradiated with light have been investigated for the development of inorganic light-activated PDT 
compounds that kill cells, but with greater specificity toward tumor cells. Light-activated 
inorganic complexes that operate similarly to cisplatin have been termed photo-cisplatin analogs. 
Two such photo-cisplatin analogs and are illustrated in Figure 3 below.12,9 
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Figure 3. photo-cisplatin analogs (a) [Ru(bpy)2(5-cyanouracil)2]2+ (bpy = 
2,2’-bipyridine) and (b) cis-H,T-[Rh2(HNOCCH3)2(CH3CN)6]2+.  
 
1.3  RUTHENIUM(II) PHOTO-CISPLATIN  ANALOGS 
Photo-cisplatin analogs containing a ruthenium, instead of a platinum, metal center 
make up a group of promising inorganic PDT agents, with several ruthenium-based agents 
already in clinical trials.13,14 A group of polypyridyl ruthenium (II) compounds of the form 
cis-[Ru(bpy)2(L)2]2+ (bpy = 2,2’-bipyridine; L = NH3, pyridine, or CH3CN) has been shown to 
exhibit the desirable qualities of PDT agents. When irradiated with visible light, these 
complexes lose their photolabile ligands in exchange for the coordination of solvent water 
molecules. The activated bis-aqua species cis-[Ru(bpy)2(H2O)2]2+ then covalently binds to 
DNA in a mechanism similar to that of cisplatin.10,15,16 These polypyridyl ruthenium 
compounds have therefore earned the title of photo-cisplatin analogs. See Figure 4 for the 
mechanism of action of cis-[Ru(bpy)2(L)2]2+. 
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Figure 4.  The mechanism of action of cis-[Ru(bpy)2(L)2]2 (L = NH3, pyridine, 
or CH3CN).  The bis-aqua species exchanges its water molecules for DNA-
binding.  
 
It has been shown in gel-electrophoresis studies that cis-[Ru(bpy)2(NH3)2]2+, cis-
[Ru(bpy)2(py)2]2+, and cis-[Ru(bpy)2(CH3CN)2]2+ inhibit the mobility of linear DNA when 
irradiated, but not in the dark, suggesting that these compounds indeed bind DNA upon 
photoactivation.10,15,16 Efficient ligand exchange occurs with light that is the same energy as 
the light that the metal complex absorbs, which is typically in the visible region, on the 
border of the PDT window.17 This requirement has led to the exploration and synthesis of 
polypyridyl ruthenium(II) complexes containing different ligands, which could alter the 
electronic properties of the compound and shift the absorption spectrum to lower energies, 
into the desired PDT window. Many of these ligands have extended π-systems (i.e. dpq, 
dppz, and dppn shown in Figure 5), which may also impart additional desirable qualities to 
the complex, such as dual-binding action through covalent DNA binding as well as DNA 
intercalation via the extended π-system. 
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Figure 5. (a) bpy = 2,2’-bipyridine (b) dpq = dipyrido [3,2-f:2',3'-h]-
quinoxaline (c) dppz = dipyrido [3,2-a:2’,3’-c] phenazine (d) dppn = benzo[i]-
dipyrido [3,2-a:2’,3’-c] phenazine. 
 
While many of these polypyridyl ruthenium(II) complexes are currently being 
studied, this work investigates ruthenium(II) complexes with cyclometallating ligands, 
which, like extended π-ligands, shift the absorbance toward red. Several cyclometallated 
ruthenium complexes have been shown to exhibit potent anti-tumor activity without many of 
the adverse side effects.18 The ligands present in the complexes studied in this work are 
shown below in Figure 6. 
 
 
 
 
Figure 6.  (a) phpy— = deprotonated 2-phenylpyridine; a cyclometallating 
ligand (b) bpy = 2,2’-bipyridine (c) phen = 1,10-phenanthroline. 
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1.4  CYCLOMETALLATED  RUTHENIUM(II)  COMPLEXES 
 The cyclometallated ruthenium(II) photo-cisplatin analog cis-
[Ru(phen)(phpy)(CH3CN)2]+ (1; phpy= 2-phenylpyridine) has been shown to inhibit the 
growth of tumors implanted in mice without severely impacting the hepatic, renal and 
nervous systems, all of which were observed to be impacted in mice treated with 
cisplatin.18,19,20 Cell cycle analysis of the tumor cells treated with 1 revealed many cells to be 
arrested in the G0/G1 phase or undergoing apoptosis.18 In subsequent studies, two groups of 
mice implanted with glioma cells were injected with either 1 or cisplatin; both treatments 
reduced the tumor size to nearly half the original size, suggesting comparable efficacy 
between the two treatments; however, mice treated with 1 suffered fewer side effects than 
mice treated with cisplatin.18 Toxicity of the two treatments was evaluated over extended 
treatment: groups of mice were injected regularly with 1 or cisplatin over a three week period 
and changes in body mass were recorded; mice treated with 1 did not experience a significant 
decrease in body mass, while mice injected with cisplatin lost nearly one fourth of their body 
mass.18 Blood analysis of these mice revealed that cisplatin-treated mice experienced altered 
levels of blood biomarkers indicative of abnormal renal and hepatic functioning, while mice 
treated with 1 did not experience these effects.18 In additional studies, treatment of 1 together 
with ionizing radiation (IR) was tested against several tumor cell lines resulting in significant 
decreases in their proliferation.19 The results described in these studies suggest that 1 and 
related compounds may possess the desired qualities of efficient PDT agents. 
Despite the striking results of the aforementioned studies and the results from recent 
studies by Sears et. al., which found that Hs-27 skin cells and H2119 lung cancer cells treated 
with 1 experienced a nearly 3-fold increase in toxicity upon irradiation (LC50dark = 7.1 µM ; 
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LC50irr = 2.7 µM), the photoactivity of 1 was not measured (LC50 is the concentration of a 
drug required to kill 50% of the dosed population).19  This nearly 3-fold increase in toxicity 
of 1 upon irradiation, is a value comparable to 5.5-fold increase in toxicity of the FDA-
approved PDT agent porfimer sodium.17 Additionally, complex 1 was found to undergo 
efficient ligand exchange when irradiated with light within the PDT window.17 Complex 1 
was also observed to decrease the mobility of linearized DNA upon irradiation, suggesting a 
DNA-binding mechanism for 1. These qualities suggest that 1 and possible analogs may 
possess the desired photochemical and photophysical qualities of PDT agents. This work 
continues to investigate the photochemical properties of 1 and its analog 2, 
[Ru(phpy)(bpy)(CH3CN)2]+.  Both complexes are shown in Figure 7. 
   
(a)          (b) 
 
 
 
 
Figure 7.  (a) 1 = [Ru(phpy)(phen)(CH3CN)2]+ (b) 2 = 
[Ru(phpy)(bpy)(CH3CN)2]+ 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It is important to note that both complex 1 and 2 contain the cyclometallating phpy— 
ligand, which extends the tail of the absorption profile of 1 and 2 into the PDT window, 
thereby making these complexes more practical as potential PDT agents. The lowest energy 
electronic transition of the previously described polypyridyl Ru(II) complexes with the 
general structure [Ru(bpy)2(L)2]2+  (L = NH3, pyridine, or CH3CN) is from Ru→bpy, a 
transition, such that it is a metal to ligand charge transfer (MLCT).  When an electron 
undergoes an MLCT transition, moving from the metal center to the bpy ligand, the complex 
is in a higher energy state and loss of the photolabile ligands can occur. This allows the 
Ru(II) complex to undergo ligand loss when irradiated and covalently bind DNA. Replacing 
one of the bpy ligands in [Ru(bpy)2(L)2]2+  with a cyclometallating ligand such as phpy–, as is 
the case in 1 and 2, lowers the energy of the MLCT transition (Ru→bpy in 2 and Ru→phen 
in 1) so that it falls into the ideal PDT window.21 
 
1.5  THE  ROLE  OF  GLUTATHIONE  IN  TOXICITY 
 Reduced glutathione (GSH) is one of the most abundant non-proteinaceous thiol-
containing molecules in the cell and its structure is illustrated in Figure 8.28 GSH functions 
primarily as an antioxidant molecule and is composed of the amino acids cysteine, glycine 
and glutamate. GSH reduces free radicals and reactive oxygen species such as H2O2 in order 
to lessen the oxidative stress.22 GSH has been shown to coordinate in metal complexes 
containing zinc, lead, mercury, and cadmium metal centers.23 Because GSH is involved in 
many biological reactions, has been shown to interact with transition metal complexes, and 
has a ubiquitous presence within the cell, its potential role in the generation of activated 
complexes of both 1 and 2 was investigated in this work.  
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Figure 8. Reduced glutathione, composed of cysteine, glycine, and glutamic 
acid. 
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CHAPTER 2 
 
EXPERIMENTAL METHODS 
 
2.1  MATERIALS 
 L-Glutathione reduced (99%) was obtained from Sigma Aldrich and L-Glutathione 
oxidized (98%) was obtained from Acros Organics. The complex cis-
[Ru(phpy)(bpy)(CH3CN)2](PF6) (2) was synthesized by Bruno Peña according to a previously 
published procedure.24 The complex cis-[Ru(phpy)(phen)(CH3CN)2](PF6) (1) was 
synthesized by Maya Ojaimi following a previously published procedure.17 
2.2  INSTRUMENTATION AND METHODS. 
A Bruker MicroTOF spectrometer was used for electrospray ionization mass 
spectrometry (ESI-MS) measurements; Bruker Daltonics Data Analysis software version 3.4 
was used to analyze ESI-MS measurements. Photolysis of 1 and was carried out in a 
borosilicate NMR tube placed at the focal point of a 150 W Xe arc lamp; a glass 1x1 cm 
cuvette was used for photolysis of 2. The wavelength of irradiation for photolysis was 
controlled with a 455 nm long-pass glass filter placed in front of the light source. Absorption 
spectra were analyzed with a Hewlett Packard 8453 diode array spectrometer and Hewlett 
Packard 8453 Win System Software. ESI-MS studies and electronic absorbance spectra were 
performed in either a DMSO:H2O solution or a CH3CN:H2O solution (33/66 or 1/99, v:v). 
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CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
3.1  ELECTRONIC ABSORBANCE OF cis-[Ru(phpy)(bpy)(CH3CN)2](PF6)  
The ground state absorption spectra of 1 and 2 in CH2Cl2 measured in the dark by 
electronic absorption spectroscopy showed complexes 1 and 2 absorbing light in the visible 
and ultraviolet regions, an expected result in comparison to absorption spectra of similar 
cyclometallated ruthenium complexes.21,25 In CH2Cl2, a ligand-centered ππ* transition occurs 
for 2 at 295 nm (ε = 61,890 M–1cm–1) and for 1 at 267 nm (ε = 96,725 M–1cm–1).25 These 
transitions are consistent with transitions observed at 293 nm (ε = 46,400 M–1cm–1) of the 
related complex [Ru(phpy)(bpy)2]+ in CH3CN.26 Also observed for [Ru(phpy)(bpy)2]+ in 
CH3CN are absorption maxima at 369 nm (ε = 8,920 M–1cm–1) and 404 nm (ε = 8,230 M–1cm–
1), which correspond to Ru→phpy– MLCT transitions;21,25 Ru→bpy MLCT transitions were 
assigned to local maxima at 492 nm (ε = 6,480 M–1cm–1) and 546 nm (ε = 7,380 M–1cm–1).21,25 
Another related complex [Ru(phpy)(CH3CN)4]+ exhibits Ru→phpy– MLCT transition at 380 
nm.24 Based on the absorption assignments of the related complexes [Ru(phpy)(bpy)2]+ and 
[Ru(phpy)(CH3CN)4]+, the maxima observed for 2 at 372 nm (ε = 13,503 M–1cm–1) and for 1 
at 396 nm (ε = 13,466 M–1cm-1) can be assigned to Ru→phpy–  MLCT transition.25,24,27 For 2, 
the absorption maxima at 472 nm (ε = 8,480 M–1cm–1) and 479 nm (ε = 8,983 M–1cm–1) were 
assigned to the Ru→bpy MLCT transitions.25 For 1, Ru→phen the MLCT transitions were 
observed with maxima at 461 nm (ε = 11,559 M–1cm–1) and 486 nm (ε = 10,842 M–1cm–1).25 
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A low energy MLCT transition that extends beyond 600 nm and into the PDT window is also 
observed for both 1 and 2, a critical feature for PDT agents.25  
Irradiation of 2 (80 µM) with visible light in CH3CN:H2O (1:99, v:v) resulted in 
changes in the absorption spectrum, suggesting that ligand exchange is occurring. The 
absorption spectrum is shown in Figure 9. 
 
 
 
 
 
 
 
 
 
 
Figure 9. Changes in the electronic absorption spectrum of 2 (80 µM) as a 
function of irradiation time was measured in CH3CN:H2O (1:99, v:v) at 0, 1, 
2, 3, 4, 5, 10, 15 min. Inset: dark control over 45 min. Irradiation done with λ 
> 455 nm light.  
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The photolysis reaction of 2 in CH3CN:H2O (1:99, v:v) was also followed by ESI-MS 
with irradiation for 15 min (λ > 475 nm) (Figure 10). Before photolysis, the major species 
present include several species. Peak A (m/z = 494.0) corresponds to the parent ion 
[Ru(phpy)(bpy)(CH3CN)2]+. A strong peak S (m/z = 440.0) is assigned to 
[Ru(phpy)(CH3CN)4]+, an impurity that corresponds to the major starting material in the 
synthesis of 2. Peak B (m/z = 453.0) is assigned to [Ru(phpy)(bpy)(CH3CN)]+. After 
irradiation for 15 min, Figure 10b demonstrates that the identities of peaks S and B do not 
change while the relative intensity of the parent ion peak A has decreased drastically with the 
emergence of the major photoproduct peak L (m/z = 429.1), which is assigned to 
[Ru(phpy)(bpy)(H2O)]+. 
 
 
 
 
 
 
   
 
Figure 10. ESI-MS of 2 (80 µM) in a CH3CN:H2O (1:99, v:v) solution (a) 
before irradiation (b) after irradiation for 15 min (λ > 475 nm). 
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3.2   THE INTERACTION OF GSH WITH cis-[Ru(phpy)(bpy)(CH3CN)2](PF6) AND 
cis-[Ru(phpy)(phen)(CH3CN)2](PF6)   
 The electronic absorption profile of 2 incubated with GSH was measured over time in 
the dark in a 1% DMSO solution, shown in Figure 11, with the corresponding dark control 
(Figure 11 inset). Upon mixing with GSH, the electronic absorption profile changes 
immediately with a general decrease in all the peaks of the starting material and the 
appearance a new band at 579 nm. 
 
 
 
 
 
 
 
 
 
Figure 11. Changes in the electronic absorption spectrum of 2 (80 µM) after 
addition of 10 equivalents of GSH was measured in the dark as a function of 
incubation time with GSH in DMSO:H2O (1:99, v:v) at 0, 1, 2, 3, 4, 5, 10, 15 
min. Inset: dark control without GSH over 45 min.  
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Since 2 was observed to undergo ligand exchange in the presence of GSH, and 
because there is a high concentration of reduced glutathione (GSH) within the cell (0.5 mM – 
10 mM GSH depending on the cell type), the possible role of GSH in contributing to the 
activation of 1 and 2 was investigated.28 The ESI-MS spectrum of 1 (670 µM) in DMSO-
d6:D2O (33:67, v:v), shows the peak denoted by A (m/z = 518.1) which corresponds to the 
parent ion of 1,  [Ru(phpy)(phen)(CH3CN)2]+ (Figure 12a). A strong peak denoted by B (m/z 
= 477.1) corresponds to the complex with loss of one CH3CN ligand, 
[Ru(phpy)(phen)(CH3CN)]+. Figure 12b illustrates that A and B are still the dominant peaks 
in the spectrum after 20 h in the dark at room temperature, suggesting that the complexes are 
stable; the emergence of a small amount of the DMSO-d6-monosubstituted product 
[Ru(phpy)(phen)(CH3CN)(DMSO-d6)]+ appears at the peak labeled C (m/z = 561.2). In 
Figure 12c, GSH was added to the sample from Figure 12b and ESI-MS was measured 20 
min following the addition. Addition of GSH resulted in the relative increase of the DMSO-
d6-monosubstituted product, denoted by peak C (m/z = 561.2) (Figure 12c). A DMSO-d6-
disubstituted product, [Ru(phpy)(phen)(DMSO-d6)2]+, in which both CH3CN ligands are lost 
and two molecules of DMSO-d6 are coordinated to the metal center, is denoted by D (m/z = 
604.2).  A peak denoted E (m/z = 577.2) also appeared and might correspond to the addition 
of a hydroxide to the product formed in C. Similar results were obtained for 2. In Figure 
12d, the peak A (m/z = 494.1) corresponds to the parent ion of 2, 
[Ru(phpy)(bpy)(CH3CN)2]+. A strong peak denoted by B (m/z = 453.1) corresponds to the 
ion with loss of one CH3CN ligand, [Ru(phpy)(bpy)(CH3CN)]+. The levels of A and B 
remain stable after 20 h in the dark (Figure 12e). Upon addition of GSH, two new peaks 
emerge (Figure 12f). The addition of GSH results in an increase in the DMSO-d6-
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monosubstituted product [Ru(phpy)(bpy)(CH3CN)(DMSO-d6)]+ denoted by peak C (m/z = 
537.2), as well as the DMSO-d6-disubstituted product [Ru(phpy)(bpy)(DMSO-d6)2]+  denoted 
by peak D (m/z = 580.2). The results presented below in Figure 12 demonstrate that GSH 
facilitates ligand loss from both 1 and 2 in exchange for coordination by DMSO-d6 
molecules.  
 
 
 
 
 
 
 
 
 
 
Figure 12. ESI-MS of 1 (670 µM) (a)–(c) and of 2 (670 µM) (d)-(f) in 
DMSO-d6:D2O (33:67, v:v) (a) and (d) correspond to time 0, immediately 
after addition of the ruthenium complexes to the DMSO-d6:D2O solution. (b) 
and (e) were measured after 20 h in the dark at room temperature. (c) and (f) 
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were measured 20 min after 10 equivalents of GSH were added to the 
respective samples described in (b) and (e). 
 
In an in vivo environment, such interaction between GSH and either 1 or 2 may result 
in ligand exchange and subsequent covalent binding to DNA in lieu of coordination by 
DMSO-d6 molecules. The ESI-MS shown in Figure 13 demonstrates the changes that occur 
when 1 is incubated for 20 h in the dark with GSH, or to a much lesser extent, with GSSG.  
 
 
  
  
 
 
 
 
 
Figure 13. ESI-MS of 1 (670 µM) in DMSO-d6:D2O (33:67, v:v) (a) 
immediately after addition of 10 equivalents of GSH to 1 in the DMSO-
d6:D2O solution (b) after 20 h in the dark at room temperature (c) after 30 min 
of irradiation (λ > 455 nm). ESI-MS of 1 (670 µM) in DMSO-d6:D2O (33:67, 
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v:v) (d) immediately after addition of 5 equivalents of GSSG to 1 in the 
DMSO-d6:D2O solution (e) after 20 h in the dark at room temperature (f) after 
30 min of irradiation. 
 
Figure 13a illustrates the spectrum of 1 incubated with GSH immediately 
after mixing. The DMSO-d6-substituted products C, E, and F are present. After 20 h 
in the dark, the DMSO-d6-disubstituted product D appears, and the relative intensities 
of C, E, D, and F increase in comparison with the parent ion, A (Figure 13b). Peak F 
corresponds to product D with an added hydroxide or oxygen atom. After irradiation, 
the identities of the products present does not change in comparison with the 
spectrum obtained before irradiation; however, it is possible that irradiation triggered 
isomerization of the DMSO molecule in DMSO-coordinated species (Figure 14). 
Such isomerization of the DMSO molecule from S-bound to O-bound form is known 
to occur upon irradiation (Figure 14).29,30 
 
 
 
 
 
Figure 14. Irradiation of the DMSO-d6-monosubstituted species 
[Ru(phpy)(phen)(CH3CN)(DMSO-d6)]+ is thought to lead to isomerization of 
the DMSO molecule from S-bound to O-bound. 
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 Because GSH is oxidized to the disulfide dimer GSSG in the presence of DMSO, it 
was necessary to assess the effect of GSSG on 1 under both dark and irradiated conditions.31 
In Figure 13d and 13e, 670 µM of 1 was incubated with 5 equivalents of GSSG in a DMSO- 
d6:D2O solution for 20 h at room temperature in the dark. A comparison between initial 
mixing of 1 and GSSG with Figure 13e 20 h later reveals an increase in the relative intensity 
of the monosubstituted product C [Ru(phpy)(phen)(CH3CN)(DMSO-d6)]+, while the 
intensity of the parent ion A does not change significantly. Subsequent photolysis of the 
sample does not have a noticeable effect on the ESI-MS spectrum (Figure 13f). 
Similar results were obtained for 2. In Figure 15, it is first important to note that peak 
S (m/z = 440.0), which is present in all spectra of Figure 13, is the impurity 
[Ru(phpy)(CH3CN)4]+, the starting material used in the synthesis of 2; the peak 
corresponding to product I (m/z = 456.1) is a photoproduct of the starting material and 
corresponds to [Ru(phpy)(CH3CN)4]+ with two associated solvent water molecules. Further 
discussion will focus on products generated from 2 and not on peaks corresponding to 
starting reagents. Figure 15 illustrates that 2 indeed interacts with GSH in a manner similar 
to the interaction observed for 1. In the ESI-MS spectrum of 1 (665 µM) mixed with 10 
equivalents of GSH in DMSO:H2O (33:67, v:v), the peak denoted by A (m/z = 494.1) 
corresponds to the parent ion [Ru(phpy)(bpy)(CH3CN)2]+ (Figure 15a). A strong peak 
denoted by B (m/z = 453.1) corresponds to the complex with loss of one CH3CN ligand,  
[Ru(phpy)(bpy)(CH3CN)]+ that is due to ionization. The relatively low intensity peak D (m/z 
= 567.0) corresponds to the small presence of a DMSO-disubstituted product 
[Ru(phpy)(bpy)(DMSO)2]+. Peak E (m/z = 613.1) corresponds to oxidized glutathione, 
GSSG. Figure 15b demonstrates that after 20 h in the dark at room temperature, both the 
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parent ion peak A and peak B are absent, while peak E has grown in relative intensity 
suggesting that much of the parent ion has reacted. Additionally, a range of DMSO-
coordinated products emerges. The strong peak F (m/z = 490.0) corresponds to a DMSO-
monosubstituted product [Ru(phpy)(bpy)(DMSO)]+. Peak G (m/z = 506.0) corresponds to 
[Ru(phpy)(bpy)(DMSO)(H2O)]+. Peak C (m/z = 531.0) corresponds to a DMSO-
monosubstituted product [Ru(phpy)(bpy)(CH3CN)(DMSO)]+. Peak J (m/z = 584.0) may 
correspond to the DMSO-disubstituted product [Ru(phpy)(bpy)(DMSO)2]+ associated with a 
solvent water molecule. In Figure 15c, the most noticeable change upon photolysis is that the 
intensities decrease due to the high relative intensity of E, which is GSSG (m/z = 613.0). 
However, photolysis does also result in the disappearance of the DMSO-monosubstituted 
product [Ru(phpy)(bpy)(CH3CN)(DMSO)]+ which corresponds to peak C, and the 
concomitant increase in the relative intensity of peak D, the DMSO-disubstituted product 
[Ru(phpy)(bpy)(DMSO)2]+. While the disappearance of the analogous peak was not observed 
for 1, it is possible that 2 is more reactive than 1. This greater reactivity of 2 is observed in 
Figure 15d-e in which reactions occur in the presence of GSH in the dark and following 
irradiation. In Figure 15d and 15e, 665 µM of 2 was incubated with 5 equivalents of GSSG 
in a DMSO:H2O solution initially and for 20 h at room temperature in the dark, respectively. 
A comparison of the ESI-MS spectra reveals a decrease in the relative intensity of product B 
[Ru(phpy)(bpy)(CH3CN)]+ and a disappearance of the parent ion A after 20 h in the dark. A 
strong peak F corresponding to a DMSO-monosubstituted product and product C also 
emerge. Photolysis of 2 in the presence of GSSG results in the disappearance of peak C and 
the increase in the relative intensity of peak D, otherwise the identities of the photoproducts 
do not differ from the products in Figure 15e. Figure 15 of 2 in the presence of either GSH 
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or GSSG clearly shows that ligand exchange and the generation of different DMSO or 
solvent coordinated products is less affected by the presence of GSH for 2 than for 1; 
however, 2 more readily achieves different substitution products in the presence of GSH than 
in the presence of GSSG, suggesting that GSH may play a role in facilitating ligand 
exchange. Furthermore, it is worth noting that even the starting material impurity, 
corresponding to peak S, achieves a different product I, in the presence of GSH, but not in 
the presence of GSSG (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. ESI-MS of 2 (665 µM) in DMSO:H2O (33:67, v:v) (a) 
immediately after addition of 10 equivalents of GSH to 2 in the DMSO:H2O 
solution (b) after 20 h in the dark at room temperature (c) after 30 min of 
irradiation (λ > 455 nm). ESI-MS of 2 (665 µM) in DMSO:H2O (33:67, v:v) 
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(d) immediately after addition of 5 equivalents of GSSG to 2 in the 
DMSO:H2O solution (e) after 20 h in the dark at room temperature (f) after 30 
min of irradiation. 
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CHAPTER 4 
 
CONCLUSION AND REFERENCES 
4.1 CONCLUSION 
 The present work illustrates that the ruthenium(II) cyclometallated complexes of 1 
and 2 have electronic absorption profiles that are shifted to lower energy wavelengths and 
into the PDT window. Upon irradiation, both 1 and 2 undergo ligand dissociation and 
coordination by solvent molecules (DMSO or H2O). Additionally, experiments conducted 
with GSH suggest that GSH interacts with both 1 and 2 to facilitate ligand exchange in both 
dark and irradiated conditions. The phototoxicity of 1 toward tumor cells in mouse models as 
well as toward cell lines may result from both photoinduced and GSH-induced ligand 
exchange.18,17 Due to the presence of DMSO in stock solutions used to solubilize 1 for cell 
viability assays, it is possible that a DMSO-coordinated species may play a role in the 
observed cytotoxicity toward tumor cell lines.29,25 Future work should address further 
characterizing the interaction between GSH and complexes 1 and 2.  
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